Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2020-06-26

AUTHORS

Viktor Grünwald, Martin H. Voss, Brian I. Rini, Thomas Powles, Laurence Albiges, Rachel H. Giles, Eric Jonasch

ABSTRACT

With the recent approval of the combinations of axitinib with the immune checkpoint inhibitor (ICI) pembrolizumab or avelumab for first-line treatment of advanced renal cell carcinoma, guidance on how to distinguish between immune-related adverse events (AEs) caused by ICI versus axitinib-related AEs is necessary to optimise therapy with axitinib–ICI combinations. The recommendations here are based on (1) systematic review of published evidence, (2) discussion among experts in the field and (3) a survey to obtain expert consensus on specific measures for therapy management with the combinations axitinib/avelumab and axitinib/pembrolizumab. The experts identified areas of AEs requiring unique management during treatment with axitinib–ICI combinations that were not covered by current recommendations. Diarrhoea, hepatic toxicity, fatigue and cardiovascular AEs were found to be applicable to such specialised management. Triage between immune-suppressive and supportive measures is a key component in therapy management. Clinical monitoring and experience with both classes of agents are necessary to manage this novel therapeutic approach. We focused on AEs with an overlap between axitinib and ICI therapy. Our recommendations address AE management of axitinib–ICI combinations with the aim to improve the safety of these therapies. More... »

PAGES

898-904

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/s41416-020-0949-9

DOI

http://dx.doi.org/10.1038/s41416-020-0949-9

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1128747011

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/32587360


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1107", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Immunology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal, Humanized", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Axitinib", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Renal Cell", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Consensus", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immune Checkpoint Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kidney Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Triage", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Interdisciplinary GU Oncology, West German Cancer Center Essen, Clinic for Urology and Clinic for Medical Oncology, University Hospital Essen, Essen, Germany", 
          "id": "http://www.grid.ac/institutes/grid.410718.b", 
          "name": [
            "Interdisciplinary GU Oncology, West German Cancer Center Essen, Clinic for Urology and Clinic for Medical Oncology, University Hospital Essen, Essen, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gr\u00fcnwald", 
        "givenName": "Viktor", 
        "id": "sg:person.01315730111.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01315730111.15"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Memorial Sloan Kettering Cancer Center, New York, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.51462.34", 
          "name": [
            "Memorial Sloan Kettering Cancer Center, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Voss", 
        "givenName": "Martin H.", 
        "id": "sg:person.0577111044.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0577111044.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA", 
          "id": "http://www.grid.ac/institutes/grid.239578.2", 
          "name": [
            "Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rini", 
        "givenName": "Brian I.", 
        "id": "sg:person.01113325143.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01113325143.17"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Barts Cancer Institute, Queen Mary University of London, London, UK", 
          "id": "http://www.grid.ac/institutes/grid.4868.2", 
          "name": [
            "Barts Cancer Institute, Queen Mary University of London, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Powles", 
        "givenName": "Thomas", 
        "id": "sg:person.0664224756.85", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0664224756.85"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Gustave Roussy Institute, Universit\u00e9 Paris Saclay, Villejuif, France", 
          "id": "http://www.grid.ac/institutes/grid.14925.3b", 
          "name": [
            "Gustave Roussy Institute, Universit\u00e9 Paris Saclay, Villejuif, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Albiges", 
        "givenName": "Laurence", 
        "id": "sg:person.01040313671.70", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01040313671.70"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "International Kidney Cancer Coalition, Duivendrecht, The Netherlands", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "International Kidney Cancer Coalition, Duivendrecht, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Giles", 
        "givenName": "Rachel H.", 
        "id": "sg:person.01311407113.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01311407113.51"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The University of Texas MD Anderson Cancer Center, Houston, TX, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "The University of Texas MD Anderson Cancer Center, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jonasch", 
        "givenName": "Eric", 
        "id": "sg:person.01172764022.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01172764022.37"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00520-018-4318-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1105214623", 
          "https://doi.org/10.1007/s00520-018-4318-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s40425-019-0746-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1122084798", 
          "https://doi.org/10.1186/s40425-019-0746-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00432-019-03002-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1120902934", 
          "https://doi.org/10.1007/s00432-019-03002-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s40425-017-0300-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092818845", 
          "https://doi.org/10.1186/s40425-017-0300-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40262-013-0068-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007267484", 
          "https://doi.org/10.1007/s40262-013-0068-3"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2020-06-26", 
    "datePublishedReg": "2020-06-26", 
    "description": "With the recent approval of the combinations of axitinib with the immune checkpoint inhibitor (ICI) pembrolizumab or avelumab for first-line treatment of advanced renal cell carcinoma, guidance on how to distinguish between immune-related adverse events (AEs) caused by ICI versus axitinib-related AEs is necessary to optimise therapy with axitinib\u2013ICI combinations. The recommendations here are based on (1) systematic review of published evidence, (2) discussion among experts in the field and (3) a survey to obtain expert consensus on specific measures for therapy management with the combinations axitinib/avelumab and axitinib/pembrolizumab. The experts identified areas of AEs requiring unique management during treatment with axitinib\u2013ICI combinations that were not covered by current recommendations. Diarrhoea, hepatic toxicity, fatigue and cardiovascular AEs were found to be applicable to such specialised management. Triage between immune-suppressive and supportive measures is a key component in therapy management. Clinical monitoring and experience with both classes of agents are necessary to manage this novel therapeutic approach. We focused on AEs with an overlap between axitinib and ICI therapy. Our recommendations address AE management of axitinib\u2013ICI combinations with the aim to improve the safety of these therapies.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/s41416-020-0949-9", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2438793", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1017082", 
        "issn": [
          "0007-0920", 
          "1532-1827"
        ], 
        "name": "British Journal of Cancer", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "6", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "123"
      }
    ], 
    "keywords": [
      "adverse events", 
      "therapy management", 
      "immune checkpoint inhibitor pembrolizumab", 
      "immune-related adverse events", 
      "advanced renal cell carcinoma", 
      "combination of axitinib", 
      "checkpoint inhibitor pembrolizumab", 
      "cardiovascular adverse events", 
      "immune checkpoint inhibitors", 
      "first-line treatment", 
      "related adverse events", 
      "renal cell carcinoma", 
      "novel therapeutic approaches", 
      "class of agents", 
      "ICI therapy", 
      "checkpoint inhibitors", 
      "AE management", 
      "cell carcinoma", 
      "hepatic toxicity", 
      "supportive measures", 
      "consensus recommendations", 
      "therapeutic approaches", 
      "current recommendations", 
      "specialised management", 
      "clinical monitoring", 
      "recent approval", 
      "expert consensus", 
      "systematic review", 
      "axitinib", 
      "therapy", 
      "treatment optimization", 
      "pembrolizumab", 
      "unique management", 
      "treatment", 
      "avelumab", 
      "management", 
      "diarrhea", 
      "carcinoma", 
      "recommendations", 
      "specific measures", 
      "triage", 
      "ICI", 
      "evidence", 
      "inhibitors", 
      "toxicity", 
      "approval", 
      "measures", 
      "events", 
      "combination", 
      "safety", 
      "review", 
      "fatigue", 
      "aim", 
      "agents", 
      "consensus", 
      "key component", 
      "experts", 
      "survey", 
      "experience", 
      "guidance", 
      "monitoring", 
      "overlap", 
      "area", 
      "components", 
      "discussion", 
      "approach", 
      "class", 
      "field", 
      "optimization"
    ], 
    "name": "Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events", 
    "pagination": "898-904", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1128747011"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/s41416-020-0949-9"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "32587360"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/s41416-020-0949-9", 
      "https://app.dimensions.ai/details/publication/pub.1128747011"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T16:06", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_863.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/s41416-020-0949-9"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/s41416-020-0949-9'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/s41416-020-0949-9'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/s41416-020-0949-9'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/s41416-020-0949-9'


 

This table displays all metadata directly associated to this object as RDF triples.

244 TRIPLES      21 PREDICATES      107 URIs      94 LITERALS      15 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/s41416-020-0949-9 schema:about N2005c170d23e47839633d3f4b90fe179
2 N25fa89236aaf4c688f0728994a15aae9
3 N36bae1f7e7934a23a496b671a999eaa2
4 N6cbcb0d710904c65a31a8a753f1e7bf3
5 Nac949a26507640419714d459c6a86997
6 Nb3e6bef7ce804141bc43718b27055f7c
7 Nd0d7e0fcdaf84c018d3eda1cad1d2721
8 Nf1acbe6f72144225847870d39be540a1
9 anzsrc-for:11
10 anzsrc-for:1107
11 schema:author N72f943dfc4d843688647a253b9a3ea45
12 schema:citation sg:pub.10.1007/s00432-019-03002-1
13 sg:pub.10.1007/s00520-018-4318-7
14 sg:pub.10.1007/s40262-013-0068-3
15 sg:pub.10.1186/s40425-017-0300-z
16 sg:pub.10.1186/s40425-019-0746-2
17 schema:datePublished 2020-06-26
18 schema:datePublishedReg 2020-06-26
19 schema:description With the recent approval of the combinations of axitinib with the immune checkpoint inhibitor (ICI) pembrolizumab or avelumab for first-line treatment of advanced renal cell carcinoma, guidance on how to distinguish between immune-related adverse events (AEs) caused by ICI versus axitinib-related AEs is necessary to optimise therapy with axitinib–ICI combinations. The recommendations here are based on (1) systematic review of published evidence, (2) discussion among experts in the field and (3) a survey to obtain expert consensus on specific measures for therapy management with the combinations axitinib/avelumab and axitinib/pembrolizumab. The experts identified areas of AEs requiring unique management during treatment with axitinib–ICI combinations that were not covered by current recommendations. Diarrhoea, hepatic toxicity, fatigue and cardiovascular AEs were found to be applicable to such specialised management. Triage between immune-suppressive and supportive measures is a key component in therapy management. Clinical monitoring and experience with both classes of agents are necessary to manage this novel therapeutic approach. We focused on AEs with an overlap between axitinib and ICI therapy. Our recommendations address AE management of axitinib–ICI combinations with the aim to improve the safety of these therapies.
20 schema:genre article
21 schema:isAccessibleForFree true
22 schema:isPartOf N8a792804a70a45089790636a1a8d9000
23 Na720b954bdc141828a9c0f2784f83370
24 sg:journal.1017082
25 schema:keywords AE management
26 ICI
27 ICI therapy
28 advanced renal cell carcinoma
29 adverse events
30 agents
31 aim
32 approach
33 approval
34 area
35 avelumab
36 axitinib
37 carcinoma
38 cardiovascular adverse events
39 cell carcinoma
40 checkpoint inhibitor pembrolizumab
41 checkpoint inhibitors
42 class
43 class of agents
44 clinical monitoring
45 combination
46 combination of axitinib
47 components
48 consensus
49 consensus recommendations
50 current recommendations
51 diarrhea
52 discussion
53 events
54 evidence
55 experience
56 expert consensus
57 experts
58 fatigue
59 field
60 first-line treatment
61 guidance
62 hepatic toxicity
63 immune checkpoint inhibitor pembrolizumab
64 immune checkpoint inhibitors
65 immune-related adverse events
66 inhibitors
67 key component
68 management
69 measures
70 monitoring
71 novel therapeutic approaches
72 optimization
73 overlap
74 pembrolizumab
75 recent approval
76 recommendations
77 related adverse events
78 renal cell carcinoma
79 review
80 safety
81 specialised management
82 specific measures
83 supportive measures
84 survey
85 systematic review
86 therapeutic approaches
87 therapy
88 therapy management
89 toxicity
90 treatment
91 treatment optimization
92 triage
93 unique management
94 schema:name Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events
95 schema:pagination 898-904
96 schema:productId N43d45d1bf13a4b15879bd614c078e9f7
97 N5388156153d04f64814f6fec1b55d956
98 Ndfde35667d98459fb6df7dec52a47130
99 schema:sameAs https://app.dimensions.ai/details/publication/pub.1128747011
100 https://doi.org/10.1038/s41416-020-0949-9
101 schema:sdDatePublished 2022-09-02T16:06
102 schema:sdLicense https://scigraph.springernature.com/explorer/license/
103 schema:sdPublisher Nd83bf426998b40f184277152dfc8a13c
104 schema:url https://doi.org/10.1038/s41416-020-0949-9
105 sgo:license sg:explorer/license/
106 sgo:sdDataset articles
107 rdf:type schema:ScholarlyArticle
108 N0ec2b57494464bfd8289e1657749cb58 rdf:first sg:person.01172764022.37
109 rdf:rest rdf:nil
110 N2005c170d23e47839633d3f4b90fe179 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Consensus
112 rdf:type schema:DefinedTerm
113 N25fa89236aaf4c688f0728994a15aae9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Humans
115 rdf:type schema:DefinedTerm
116 N26907bc2858546e88043e4c508c34b96 rdf:first sg:person.0577111044.36
117 rdf:rest N5e638984424c47b3a268c7da33c51f04
118 N36bae1f7e7934a23a496b671a999eaa2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Immune Checkpoint Inhibitors
120 rdf:type schema:DefinedTerm
121 N43d45d1bf13a4b15879bd614c078e9f7 schema:name dimensions_id
122 schema:value pub.1128747011
123 rdf:type schema:PropertyValue
124 N5388156153d04f64814f6fec1b55d956 schema:name pubmed_id
125 schema:value 32587360
126 rdf:type schema:PropertyValue
127 N5e638984424c47b3a268c7da33c51f04 rdf:first sg:person.01113325143.17
128 rdf:rest Nf550eba9365e42119669c24741d45e12
129 N6cbcb0d710904c65a31a8a753f1e7bf3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Carcinoma, Renal Cell
131 rdf:type schema:DefinedTerm
132 N72f943dfc4d843688647a253b9a3ea45 rdf:first sg:person.01315730111.15
133 rdf:rest N26907bc2858546e88043e4c508c34b96
134 N849a992f98de4f49a9b90ae21e12f688 rdf:first sg:person.01311407113.51
135 rdf:rest N0ec2b57494464bfd8289e1657749cb58
136 N8a159b51778c4e78b1b322bfab37cf7c rdf:first sg:person.01040313671.70
137 rdf:rest N849a992f98de4f49a9b90ae21e12f688
138 N8a792804a70a45089790636a1a8d9000 schema:volumeNumber 123
139 rdf:type schema:PublicationVolume
140 Na720b954bdc141828a9c0f2784f83370 schema:issueNumber 6
141 rdf:type schema:PublicationIssue
142 Nac949a26507640419714d459c6a86997 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Kidney Neoplasms
144 rdf:type schema:DefinedTerm
145 Nb3e6bef7ce804141bc43718b27055f7c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Axitinib
147 rdf:type schema:DefinedTerm
148 Nd0d7e0fcdaf84c018d3eda1cad1d2721 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Antibodies, Monoclonal, Humanized
150 rdf:type schema:DefinedTerm
151 Nd83bf426998b40f184277152dfc8a13c schema:name Springer Nature - SN SciGraph project
152 rdf:type schema:Organization
153 Ndfde35667d98459fb6df7dec52a47130 schema:name doi
154 schema:value 10.1038/s41416-020-0949-9
155 rdf:type schema:PropertyValue
156 Nf1acbe6f72144225847870d39be540a1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Triage
158 rdf:type schema:DefinedTerm
159 Nf550eba9365e42119669c24741d45e12 rdf:first sg:person.0664224756.85
160 rdf:rest N8a159b51778c4e78b1b322bfab37cf7c
161 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
162 schema:name Medical and Health Sciences
163 rdf:type schema:DefinedTerm
164 anzsrc-for:1107 schema:inDefinedTermSet anzsrc-for:
165 schema:name Immunology
166 rdf:type schema:DefinedTerm
167 sg:grant.2438793 http://pending.schema.org/fundedItem sg:pub.10.1038/s41416-020-0949-9
168 rdf:type schema:MonetaryGrant
169 sg:journal.1017082 schema:issn 0007-0920
170 1532-1827
171 schema:name British Journal of Cancer
172 schema:publisher Springer Nature
173 rdf:type schema:Periodical
174 sg:person.01040313671.70 schema:affiliation grid-institutes:grid.14925.3b
175 schema:familyName Albiges
176 schema:givenName Laurence
177 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01040313671.70
178 rdf:type schema:Person
179 sg:person.01113325143.17 schema:affiliation grid-institutes:grid.239578.2
180 schema:familyName Rini
181 schema:givenName Brian I.
182 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01113325143.17
183 rdf:type schema:Person
184 sg:person.01172764022.37 schema:affiliation grid-institutes:grid.240145.6
185 schema:familyName Jonasch
186 schema:givenName Eric
187 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01172764022.37
188 rdf:type schema:Person
189 sg:person.01311407113.51 schema:affiliation grid-institutes:None
190 schema:familyName Giles
191 schema:givenName Rachel H.
192 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01311407113.51
193 rdf:type schema:Person
194 sg:person.01315730111.15 schema:affiliation grid-institutes:grid.410718.b
195 schema:familyName Grünwald
196 schema:givenName Viktor
197 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01315730111.15
198 rdf:type schema:Person
199 sg:person.0577111044.36 schema:affiliation grid-institutes:grid.51462.34
200 schema:familyName Voss
201 schema:givenName Martin H.
202 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0577111044.36
203 rdf:type schema:Person
204 sg:person.0664224756.85 schema:affiliation grid-institutes:grid.4868.2
205 schema:familyName Powles
206 schema:givenName Thomas
207 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0664224756.85
208 rdf:type schema:Person
209 sg:pub.10.1007/s00432-019-03002-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1120902934
210 https://doi.org/10.1007/s00432-019-03002-1
211 rdf:type schema:CreativeWork
212 sg:pub.10.1007/s00520-018-4318-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1105214623
213 https://doi.org/10.1007/s00520-018-4318-7
214 rdf:type schema:CreativeWork
215 sg:pub.10.1007/s40262-013-0068-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007267484
216 https://doi.org/10.1007/s40262-013-0068-3
217 rdf:type schema:CreativeWork
218 sg:pub.10.1186/s40425-017-0300-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1092818845
219 https://doi.org/10.1186/s40425-017-0300-z
220 rdf:type schema:CreativeWork
221 sg:pub.10.1186/s40425-019-0746-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1122084798
222 https://doi.org/10.1186/s40425-019-0746-2
223 rdf:type schema:CreativeWork
224 grid-institutes:None schema:alternateName International Kidney Cancer Coalition, Duivendrecht, The Netherlands
225 schema:name International Kidney Cancer Coalition, Duivendrecht, The Netherlands
226 rdf:type schema:Organization
227 grid-institutes:grid.14925.3b schema:alternateName Gustave Roussy Institute, Université Paris Saclay, Villejuif, France
228 schema:name Gustave Roussy Institute, Université Paris Saclay, Villejuif, France
229 rdf:type schema:Organization
230 grid-institutes:grid.239578.2 schema:alternateName Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA
231 schema:name Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA
232 rdf:type schema:Organization
233 grid-institutes:grid.240145.6 schema:alternateName The University of Texas MD Anderson Cancer Center, Houston, TX, USA
234 schema:name The University of Texas MD Anderson Cancer Center, Houston, TX, USA
235 rdf:type schema:Organization
236 grid-institutes:grid.410718.b schema:alternateName Interdisciplinary GU Oncology, West German Cancer Center Essen, Clinic for Urology and Clinic for Medical Oncology, University Hospital Essen, Essen, Germany
237 schema:name Interdisciplinary GU Oncology, West German Cancer Center Essen, Clinic for Urology and Clinic for Medical Oncology, University Hospital Essen, Essen, Germany
238 rdf:type schema:Organization
239 grid-institutes:grid.4868.2 schema:alternateName Barts Cancer Institute, Queen Mary University of London, London, UK
240 schema:name Barts Cancer Institute, Queen Mary University of London, London, UK
241 rdf:type schema:Organization
242 grid-institutes:grid.51462.34 schema:alternateName Memorial Sloan Kettering Cancer Center, New York, NY, USA
243 schema:name Memorial Sloan Kettering Cancer Center, New York, NY, USA
244 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...